Regeneron enters radiopharma ring with up to $4.3B Telix alliance
Telix is Regeneron’s entry ticket into the radiopharma game, helping to better round out the company’s cancer portfolio, according to Truist Securities.
Regeneron enters radiopharma ring with up to $4.3B Telix alliance Read More »
